November 11th 2024
Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.
October 31st 2024
Your daily dose of the clinical news you may have missed.
October 29th 2024
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
October 9th 2024
Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.
October 8th 2024